CD79bdirected

CD79bdirected refers to therapeutic strategies that target CD79b, a transmembrane protein that forms part of the B cell receptor complex with CD79a. CD79b contains an ITAM motif and participates in signal transduction after antigen engagement, contributing to B cell activation and survival.

CD79bdirected therapies exploit the biology of CD79b expressed on most mature B cells and in many B-cell malignancies, including various non-Hodgkin lymphomas and chronic lymphocytic leukemia. This provides a rationale for targeted therapy aimed at malignant B cells while attempting to limit activity on non-B cells.

Therapeutic approaches include monoclonal antibodies directed at CD79b, antibody-drug conjugates (ADCs) that deliver cytotoxic payload upon internalization, and newer modalities such as bispecific antibodies or cellular therapies exploring CD79bdirected targets.

Polatuzumab vedotin is an example of a CD79bdirected ADC. It combines a CD79b-targeting antibody with monomethyl auristatin E, a microtubule-disrupting agent. In clinical development, CD79bdirected therapies are studied in various regimens and across B-cell lymphomas, aiming to improve outcomes in relapsed or refractory disease.

Potential adverse effects include cytopenias, infections, neuropathies, and infusion reactions due to on-target effects on normal B cells. Research continues to optimize selectivity, manage toxicity, and expand indications. The term CD79bdirected is used in pharmacology and oncology to categorize agents whose primary target is CD79b.